TD Cowen keeps USD 17 target for Sarepta Therapeutics stock

Published on 10/22/2026 at 14:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sarepta Therapeutics stock is at EUR 16.36 on October 22, 2026. Second-quarter revenue was USD 401.3 million, down 34.3 percent year over year.

Research data and analyst view

TD Cowen maintained a Hold rating and a USD 17.00 target on October 21, 2026.
Sarepta reported up to 80 percent SRP-1003 knockdown in preclinical DM1 models on October 14, 2026.
Sarepta Therapeutics stock traded at EUR 16.36 at 2:13 p.m. CEST at Lang & Schwarz on October 22, 2026.
Second-quarter revenue reached USD 401.3 million for the period ended June 30, 2026.

SRPT, US8036071004, Illustration mit AI erstellt.

Sarepta Therapeutics (ISIN US8036071004) traded at EUR 16.36 at Lang & Schwarz on October 22, 2026, at 2:13 p.m. CEST. Markets Insider reported on October 21, 2026, that TD Cowen maintained a Hold rating and a USD 17.00 price target for the company.

The latest analyst view

TD Cowen's stance puts the stock near a key evidence point: Sarepta's second-quarter results showed USD 401.3 million in revenue for the period ended June 30, 2026, according to Markets Insider. That was down 34.3 percent from USD 611.09 million in the comparable period, while the company posted a GAAP net loss of USD 4.89 million.

Three dated signals

The recent sequence began on October 14, 2026, when BioSpace carried Sarepta's release on SRP-1003 data showing up to 80 percent knockdown of pathogenic DMPK RNA in preclinical models. On October 19, 2026, Investing.com reported that H.C. Wainwright reiterated a Sell rating with a USD 5.00 target. TD Cowen's USD 17.00 Hold target followed on October 21, 2026.

What comes next for Sarepta?

The next scheduled reporting date is November 2, 2026, according to MetaCap. The company also expects additional Phase 1/2 results for SRP-1003 later in 2026, making clinical data the next measurable test for the pipeline narrative.

Stock quote in euros

Sarepta's euro quote stood at EUR 16.36 at Lang & Schwarz on October 22, 2026, at 2:13 p.m. CEST. The stock's Nasdaq listing is denominated in USD, so the analyst targets and reported financial figures remain separate from the euro quotation. The further course of trading is shown by the continuously updated real-time quote of Sarepta Therapeutics stock.